Brian Liu, MD, is a Managing Director at Longitude Capital. Dr. Liu serves on the board of directors at CG Oncology and is a board observer at Quanta Therapeutics, Rivus Pharmaceuticals, and Zenas BioPharma. He previously served as a board observer at Endeavor Biomedicines, Inflazome (acquired by Roche), Talaris Therapeutics (TALS), and Vera Therapeutics (VERA). Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University.
